<DOC>
	<DOCNO>NCT01973790</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety 100 mg Z-338 TID European subject FD .</brief_summary>
	<brief_title>Phase III , Long-term , Open-label Safety Study Z-338</brief_title>
	<detailed_description>This Phase III , multicentre , single-arm , open-label study evaluate long-term safety 100 mg Z-338 TID subject FD . The study comprise screen period ( 3 week ) , run-in period ( 1 week ) open-label treatment period ( 52 week ) . Including additional 2-week follow-up period assessment AEs , maximum duration subject 's participation study 58 week .</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<criteria>Subjects provide write informed consent prior study procedure perform Subjects diagnosis FD ( postprandial distress syndrome ) define Rome III Criteria Subjects must present Postprandial Fullness Early Satiation bothersome symptom 6 month prior inform consent . Subjects must normal endoscopy result within 6 month ( 3 month case subject Helicobacter pylorus positive ) prior inform consent screen period . Subjects PPI ( ) unable discontinue PPI medication end screen period Subjects take drug affect gut motility , gut sensitivity and/or acid secretion unable discontinue drug end screen period Subjects receive H. pylori eradication therapy 3 month prior inform consent Subjects confirm organic gastrointestinal disease Subjects presenting predominant complaint relieve stool movement ( irritable bowel syndrome ) Subjects present predominant GORD symptoms Subjects present predominant complaint chronic idiopathic nausea Subjects Type I Type II diabetes Subjects body mass index ( BMI ) 30 kg/m2 Subjects condition , opinion Investigator , make subject unsuitable entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Z-338</keyword>
	<keyword>Functional Dyspepsia</keyword>
	<keyword>Postprandial Distress Syndrome</keyword>
</DOC>